AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Phospholipid phosphatase 2

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.

Our library is unique due to several crucial aspects:

  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

O43688

UPID:

PLPP2_HUMAN

Alternative names:

Lipid phosphate phosphohydrolase 2; PAP2-gamma; Phosphatidate phosphohydrolase type 2c; Phosphatidic acid phosphatase 2c

Alternative UPACC:

O43688; A6NLV0; E9PAY8

Background:

Phospholipid phosphatase 2, known by alternative names such as Lipid phosphate phosphohydrolase 2 and Phosphatidic acid phosphatase 2c, plays a crucial role in cellular processes by catalyzing the dephosphorylation of various lipid phosphate esters. This enzyme operates independently of magnesium and targets a wide range of substrates including phosphatidate, lysophosphatidate, sphingosine 1-phosphate, and ceramide 1-phosphate, thereby producing bioactive compounds that may influence signal transduction pathways.

Therapeutic significance:

Understanding the role of Phospholipid phosphatase 2 could open doors to potential therapeutic strategies. Its involvement in the regulation of cell cycle transition and signal transduction highlights its potential as a target for therapeutic intervention in diseases where these processes are dysregulated.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.